Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)

被引：0
|
作者：
Akio Nakasya
Yuya Hagiwara
Tatsuki Ikoma
Yusuke Kurioka
Toshihiko Matsumoto
Yoshiyuki Yamamoto
Takao Tsuduki
Takeshi Kajiwara
Toshikazu Moriwaki
Tomohiro Nishina
Natsumi Yamashita
Ichinosuke Hyodo
机构：
[1] National Hospital Organization Shikoku Cancer Center,Department of Gastrointestinal Medical Oncology
[2] University of Tsukuba,Department of Gastroenterology, Faculty of Medicine
[3] Kobe City Medical Center General Hospital,Department of Medical Oncology
[4] Himeji Red Cross Hospital,Department of Internal Medicine
[5] National Hospital Organization Shikoku Cancer Center,Section of Cancer Prevention and Epidemiology, Clinical Research Center
来源：
International Journal of Clinical Oncology | 2022年 / 27卷
关键词：
Gastric cancer; Chemotherapy; Albumin-bound paclitaxel; Paclitaxel; Ramucirumab; Propensity score;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：684 / 694
页数：10
相关论文
共 50 条
  • [21] FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel- results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO
    Lorenzen, Sylvie
    Thuss-Patience, Peter
    Pauligk, Claudia
    Goekkurt, Eray
    Ettrich, Thomas
    Lordick, Florian
    Stahl, Michael
    Reichardt, Peter
    Soekler, Martin
    Pink, Daniel
    Probst, Stefan
    Hinke, Axel
    Goetze, Thorsten O.
    Al-Batran, Salah E.
    EUROPEAN JOURNAL OF CANCER, 2022, 165 : 48 - 57
  • [22] Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
    Han, Hye Sook
    Kim, Bum Jun
    Jee, Hee-Jung
    Ryu, Min-Hee
    Park, Se Hoon
    Rha, Sun Young
    Kim, Jong Gwang
    Bae, Woo Kyun
    Lee, Keun-Wook
    Oh, Do-Youn
    Kim, In-Ho
    Sym, Sun Jin
    Oh, So Yeon
    Kim, Hyeong Su
    Byun, Ji-Hye
    Kim, Dong Sook
    Suh, Young Ju
    An, Hyonggin
    Zang, Dae Young
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [23] Preoperative versus postoperative chemo-radiotherapy for locally advanced gastric cancer: a multicenter propensity score-matched analysis
    Li, Ning
    Xiang, Xiaoyong
    Zhao, Dongbin
    Wang, Xin
    Tang, Yuan
    Chi, Yihebali
    Yang, Lin
    Jiang, Liming
    Jiang, Jun
    Shi, Jinming
    Liu, Wenyang
    Fang, Hui
    Tang, Yu
    Chen, Bo
    Lu, Ningning
    Jing, Hao
    Qi, Shunan
    Wang, Shulian
    Liu, Yueping
    Song, Yongwen
    Li, Yexiong
    Zhang, Liyuan
    Jin, Jing
    BMC CANCER, 2022, 22 (01)
  • [24] Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer
    Anzai, Masaki
    Morikawa, Miwa
    Okuno, Takehiro
    Umeda, Yukihiro
    Demura, Yoshiki
    Sonoda, Tomoaki
    Yamaguchi, Makiko
    Kanno, Kiyoshi
    Shiozaki, Kohei
    Ameshima, Shingo
    Akai, Masaya
    Ishizuka, Tamotsu
    MEDICINE, 2017, 96 (51)
  • [25] Preoperative versus postoperative chemo-radiotherapy for locally advanced gastric cancer: a multicenter propensity score-matched analysis
    Ning Li
    Xiaoyong Xiang
    Dongbin Zhao
    Xin Wang
    Yuan Tang
    Yihebali Chi
    Lin Yang
    Liming Jiang
    Jun Jiang
    Jinming Shi
    Wenyang Liu
    Hui Fang
    Yu Tang
    Bo Chen
    Ningning Lu
    Hao Jing
    Shunan Qi
    Shulian Wang
    Yueping Liu
    Yongwen Song
    Yexiong Li
    Liyuan Zhang
    Jing Jin
    BMC Cancer, 22
  • [26] The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY)
    Tanioka, Hiroaki
    Nagasaka, Takeshi
    Uno, Futoshi
    Inoue, Masafumi
    Okita, Hiroyuki
    Katata, Yosuke
    Kanzaki, Hiromitsu
    Kuramochi, Hidekazu
    Satake, Hironaga
    Shindo, Yoshiaki
    Doi, Akira
    Nasu, Jyunichiro
    Yamashita, Haruhiro
    Yamaguchi, Yoshiyuki
    BMC CANCER, 2019, 19 (01)
  • [27] Identifying prognostic factors associated with overall survival in second-line paclitaxel plus ramucirumab treated human epidermal growth factor receptor 2-negative advanced/recurrent gastric cancer
    Kimura, M.
    Usami, E.
    Teramachi, H.
    Yoshimura, T.
    PHARMAZIE, 2021, 76 (07): : 328 - 333
  • [28] Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group
    Hirata, Kenro
    Hamamoto, Yasuo
    Ando, Masahiko
    Imamura, Chiyo K.
    Yoshimura, Kenichi
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Muro, Kei
    BMC CANCER, 2020, 20 (01)
  • [29] Pairwise analysis of plasma cell-free DNA before and after palliative second-line paclitaxel plus ramucirumab treatment in patients with metastatic gastric cancer
    Kim, Ji-Won
    Kyung, Dong Soo
    Ko, Won Yeong
    Kim, Hwang-Phill
    Hwang, Sung-Hyun
    Kim, Kui-Jin
    Lee, Ju Hyun
    Seo, Jeongmin
    Kang, Minsu
    Jung, Eun Hee
    Suh, Koung Jin
    Kim, Se Hyun
    Kim, Jin Won
    Kim, Yu Jung
    Kim, Jee Hyun
    Lee, Keun-Wook
    GASTRIC CANCER, 2025,
  • [30] Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)
    Bum Jun Kim
    Hee-Jung Jee
    Sun Young Rha
    Hye Sook Han
    Min-Hee Ryu
    Se Hoon Park
    Jong Gwang Kim
    Woo Kyun Bae
    Keun-Wook Lee
    Do-Youn Oh
    Ji-Hye Byun
    Dong Sook Kim
    Young Ju Suh
    Hyonggin An
    Dae Young Zang
    Gastric Cancer, 2022, 25 : 609 - 618
12345